In the modern landscape of obesity and metabolic pharmacology, GLP-1 receptor agonists such as Semaglutide (Wegovy/Ozempic) and dual GIP/GLP-1 agonists like Tirzepatide (Zepbound/Mounjaro) have revolutionized weight management. Patients routinely achieve 15% to 22% total body weight reduction through appetite suppression and delayed gastric emptying.However, clinical endocrinologists and researchers face a persistent challenge: the post-GLP-1…